MA41415A - Dinucléotides cycliques utiles pour traiter, entre autres, le cancer - Google Patents
Dinucléotides cycliques utiles pour traiter, entre autres, le cancerInfo
- Publication number
- MA41415A MA41415A MA041415A MA41415A MA41415A MA 41415 A MA41415 A MA 41415A MA 041415 A MA041415 A MA 041415A MA 41415 A MA41415 A MA 41415A MA 41415 A MA41415 A MA 41415A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- treating
- cyclic dinucleotides
- useful
- dinucleotides useful
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501462.4A GB201501462D0 (en) | 2015-01-29 | 2015-01-29 | Novel compounds |
| US201562262621P | 2015-12-03 | 2015-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41415A true MA41415A (fr) | 2017-12-05 |
Family
ID=52705427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041415A MA41415A (fr) | 2015-01-29 | 2016-01-26 | Dinucléotides cycliques utiles pour traiter, entre autres, le cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10047115B2 (fr) |
| EP (1) | EP3250573A1 (fr) |
| JP (1) | JP6722682B2 (fr) |
| KR (1) | KR20170102362A (fr) |
| CN (1) | CN107108684B (fr) |
| AU (1) | AU2016212085B2 (fr) |
| BR (1) | BR112017016006A2 (fr) |
| CA (1) | CA2973806A1 (fr) |
| CL (1) | CL2017001932A1 (fr) |
| CO (1) | CO2017007293A2 (fr) |
| CR (1) | CR20170350A (fr) |
| DO (1) | DOP2017000175A (fr) |
| EA (1) | EA031728B1 (fr) |
| GB (1) | GB201501462D0 (fr) |
| IL (1) | IL252935A0 (fr) |
| MA (1) | MA41415A (fr) |
| MX (1) | MX2017009837A (fr) |
| PE (1) | PE20171322A1 (fr) |
| PH (1) | PH12017501233A1 (fr) |
| SG (1) | SG11201705077VA (fr) |
| WO (1) | WO2016120305A1 (fr) |
| ZA (1) | ZA201704732B (fr) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| SG10201708821RA (en) | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2979215A1 (fr) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions et procedes d'activation de la signalisation dependante de « stimulateur de genes d'interferon » |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MA42608A (fr) * | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| CN108430503A (zh) * | 2015-10-28 | 2018-08-21 | 艾杜罗生物科技公司 | 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| CA3006930A1 (fr) * | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Dinucleotides cycliques de purine a titre de modulateurs du sting |
| KR20250049441A (ko) | 2016-01-11 | 2025-04-11 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| EP3429596B1 (fr) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Composés di-nucléotides cycliques et leurs procédés d'utilisation |
| US10696985B1 (en) | 2016-06-06 | 2020-06-30 | Vanderbilt University | Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery |
| WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
| KR102569881B1 (ko) | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| US10537590B2 (en) * | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
| US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200113924A1 (en) * | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| EP3573718B1 (fr) * | 2017-01-27 | 2022-06-01 | Janssen Biotech, Inc. | Dinucléotides cycliques utilisés en tant qu'agonistes de sting |
| US11021511B2 (en) | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| WO2018156625A1 (fr) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Dinucléotides cycliques utilisés en tant qu'agonistes du stimulateur de la signalisation dépendante du gène de l'interféron |
| JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| WO2018195070A1 (fr) * | 2017-04-17 | 2018-10-25 | Memorial Sloan-Kettering Cancer Center | Effet protecteur de l'intestin obtenu par l'activation de rig-i/mavs et de sting |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| WO2019027857A1 (fr) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b]thiophéniques pour le traitement du cancer |
| JP2020530838A (ja) * | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| WO2019043634A2 (fr) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Di-nucléotides cycliques en tant que stimulateurs de modulateurs de gènes d'interféron |
| WO2019046496A1 (fr) * | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Dinucléotides cycliques utilisés en tant qu'agents anticancéreux |
| WO2019046511A1 (fr) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes pour le traitement d'une maladie |
| WO2019046498A1 (fr) * | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Dinucléotides cycliques utilisés en tant qu'agents anticancéreux |
| JP7208225B2 (ja) * | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051489A1 (fr) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| WO2019084060A1 (fr) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugués et leurs procédés d'utilisation pour l'administration sélective d'agents immunomodulateurs |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| WO2019125974A1 (fr) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (fr) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
| CN110016025B (zh) * | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| CN110272462B (zh) * | 2018-03-15 | 2023-03-10 | 南开大学 | 制备化合物的方法 |
| TWI741268B (zh) * | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑 |
| TW202003032A (zh) | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含ｓ ｔ ｉ ｎ ｇ 促效劑之胞外囊泡 |
| US20210015915A1 (en) | 2018-03-23 | 2021-01-21 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| CN111971291A (zh) | 2018-03-27 | 2020-11-20 | 勃林格殷格翰国际有限公司 | 用作sting激动剂的含有2-氮杂-次黄嘌呤或6h-吡唑并[1,5-d][1,2,4]三嗪-7-酮的环状二核苷酸化合物 |
| EP3774833A1 (fr) | 2018-03-27 | 2021-02-17 | Boehringer Ingelheim International GmbH | Composés dinucléotidiques cycliques modifiés |
| WO2019195124A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting |
| WO2019195063A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
| TWI833744B (zh) * | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US10947227B2 (en) | 2018-05-25 | 2021-03-16 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| JP7335277B2 (ja) * | 2018-06-01 | 2023-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膀胱がんの治療のための方法 |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2020010451A1 (fr) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Amides imidazolyle hétéroaromatiques fusionnés, compositions et utilisations de ceux-ci en tant qu'agonistes de sting |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020036199A1 (fr) | 2018-08-16 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Sels de composés et cristaux de ceux-ci |
| MA53438A (fr) | 2018-08-24 | 2021-09-15 | Codiak Biosciences Inc | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| WO2020057546A1 (fr) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation |
| US12508233B2 (en) | 2018-10-30 | 2025-12-30 | Vanderbilt University | Graft copolymers, methods of forming graft copolymers, and methods of use thereof |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020146237A1 (fr) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Composés d'amide d'hétéroaryle en tant qu'activateurs de sting |
| CN113645977A (zh) * | 2019-03-05 | 2021-11-12 | F-星治疗公司 | 化合物、组合物和疾病治疗方法 |
| EP3934757B1 (fr) * | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
| CA3129011C (fr) * | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 3'3'-cycliques et leurs promedicaments |
| BR112021018694A2 (pt) | 2019-03-21 | 2021-11-30 | Codiak Biosciences Inc | Vesículas extracelulares para distribuição de vacina |
| EP3946370A4 (fr) * | 2019-03-29 | 2023-01-04 | Merck Sharp & Dohme LLC | Formulations stables de composés agonistes de sting à base de dinucléotides cycliques et leurs méthodes d'utilisation |
| EP3946324B1 (fr) | 2019-04-04 | 2025-07-30 | Merck Sharp & Dohme LLC | Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète |
| US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| CA3139809A1 (fr) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Conjugues anticorps-medicament |
| WO2021003445A1 (fr) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations |
| CA3145889A1 (fr) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctene et leurs utilisations dans le traitement du cancer et l'immunotherapie |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| EP3789393A1 (fr) * | 2019-09-06 | 2021-03-10 | Centre National de la Recherche Scientifique | Inhibiteurs de piqûre et leurs utilisations thérapeutiques |
| JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ， インコーポレイテッド | 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用 |
| EP4034081A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Compositions de vésicules extracellulaires |
| EP4034276A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| CA3151322A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polytherapie comprenant des conjugues immunostimulants |
| EP4069683A1 (fr) | 2019-12-06 | 2022-10-12 | Mersana Therapeutics, Inc. | Composés dimères utilisés en tant qu'agonistes de sting |
| EP4106819A1 (fr) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| AU2021236763A1 (en) | 2020-03-20 | 2022-10-06 | Lonza Sales Ag | Extracellular vesicles for therapy |
| AU2021248635B2 (en) | 2020-04-02 | 2025-10-23 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising STING agonists |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| EP4216993A2 (fr) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
| WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
| EP4240488A1 (fr) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Conjugués anticorps-médicament |
| WO2023056468A1 (fr) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Vésicule extracellulaire comprenant un agoniste de sting marqué au cholestérol |
| WO2026027944A1 (fr) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Formulations d'anticorps anti-sirp alpha et leurs utilisations |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| WO2005005450A1 (fr) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | Procede de synthese d'un bisdinucleoside cyclique |
| CA2533873A1 (fr) | 2003-07-28 | 2005-04-07 | David K.R. Karaolis | Procede permettant d'attenuer la virulence d'agents pathogenes microbiens et d'inhiber la formation d'un biofilm microbien |
| US20050187278A1 (en) | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| JP4887284B2 (ja) | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
| EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
| WO2009133560A1 (fr) | 2008-04-29 | 2009-11-05 | Smart Assays | Dérivés de bis-(nucléotide monophosphate) cycliques non hydrolysables et perméables et leurs utilisations |
| WO2013166000A1 (fr) | 2012-04-30 | 2013-11-07 | Barber Glen N | Modulation de réponses immunitaires |
| WO2011003025A1 (fr) | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthèse de monophosphate de diguanosine cyclique et de leurs analogues thiophosphate |
| US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
| US20120288515A1 (en) | 2011-04-27 | 2012-11-15 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
| WO2013086331A1 (fr) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | Cyclase di-nucléotide à haute efficacité |
| JP5650780B2 (ja) | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | ワクチン組成物 |
| JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック，インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| US20140170689A1 (en) | 2012-12-12 | 2014-06-19 | The Research Foundation For The State University Of New York | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP |
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| EP3398616A3 (fr) * | 2012-12-19 | 2019-01-30 | Board of Regents, The University of Texas System | Ciblage pharmaceutique d'une voie de signalisation de dinucléotide cyclique chez un mammifère |
| SG10201708821RA (en) | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| ES2754269T3 (es) * | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| WO2015108595A1 (fr) | 2014-01-15 | 2015-07-23 | Nikolai Khodarev | Thérapie anti-tumorale |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| CA2950863C (fr) | 2014-06-02 | 2023-01-17 | Isa Pharmaceuticals B.V. | Peptides longs synthetiques (slp) destines a la vaccination therapeutique contre l'infection par le virus de l'hepatite b |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
| CN107148424B (zh) * | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| EP3233191A1 (fr) | 2014-12-16 | 2017-10-25 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| EP3233089A4 (fr) | 2014-12-17 | 2018-11-14 | Lipogen LLC | Procédé de traitement du cancer avec cgamp ou cgasmp |
| WO2016115480A1 (fr) | 2015-01-16 | 2016-07-21 | Vedantra Pharmaceuticals, Inc. | Compositions de vésicules lipidiques multilamellaires comprenant un variant de kinase du lymphome anaplasique (alk) conjugué et leurs utilisations |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3250250A4 (fr) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Matériaux péritumoraux et intratumoraux pour traitement anticancéreux |
| US20160220652A1 (en) | 2015-02-03 | 2016-08-04 | Advaxis, Inc. | Methods of using recombinant listeria vaccine strains in disease immunotherapy |
| CA3014427A1 (fr) | 2015-02-13 | 2016-08-18 | Icahn School Of Medicine At Mount Sinai | Compositions contenant de l'arn et leurs methodes d'utilisation |
| CA2979215A1 (fr) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions et procedes d'activation de la signalisation dependante de « stimulateur de genes d'interferon » |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| CN108430503A (zh) | 2015-10-28 | 2018-08-21 | 艾杜罗生物科技公司 | 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
-
2015
- 2015-01-29 GB GBGB1501462.4A patent/GB201501462D0/en not_active Ceased
-
2016
- 2016-01-26 MA MA041415A patent/MA41415A/fr unknown
- 2016-01-27 AU AU2016212085A patent/AU2016212085B2/en not_active Ceased
- 2016-01-27 BR BR112017016006A patent/BR112017016006A2/pt not_active Application Discontinuation
- 2016-01-27 JP JP2017539658A patent/JP6722682B2/ja not_active Expired - Fee Related
- 2016-01-27 US US15/543,007 patent/US10047115B2/en not_active Expired - Fee Related
- 2016-01-27 MX MX2017009837A patent/MX2017009837A/es unknown
- 2016-01-27 CN CN201680006178.4A patent/CN107108684B/zh not_active Expired - Fee Related
- 2016-01-27 EA EA201791607A patent/EA031728B1/ru not_active IP Right Cessation
- 2016-01-27 WO PCT/EP2016/051654 patent/WO2016120305A1/fr not_active Ceased
- 2016-01-27 EP EP16702069.2A patent/EP3250573A1/fr not_active Withdrawn
- 2016-01-27 KR KR1020177022778A patent/KR20170102362A/ko not_active Withdrawn
- 2016-01-27 SG SG11201705077VA patent/SG11201705077VA/en unknown
- 2016-01-27 CA CA2973806A patent/CA2973806A1/fr not_active Abandoned
- 2016-01-27 PE PE2017001269A patent/PE20171322A1/es not_active Application Discontinuation
- 2016-01-27 CR CR20170350A patent/CR20170350A/es unknown
-
2017
- 2017-06-15 IL IL252935A patent/IL252935A0/en unknown
- 2017-07-03 PH PH12017501233A patent/PH12017501233A1/en unknown
- 2017-07-13 ZA ZA2017/04732A patent/ZA201704732B/en unknown
- 2017-07-21 CO CONC2017/0007293A patent/CO2017007293A2/es unknown
- 2017-07-28 DO DO2017000175A patent/DOP2017000175A/es unknown
- 2017-07-28 CL CL2017001932A patent/CL2017001932A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201501462D0 (en) | 2015-03-18 |
| KR20170102362A (ko) | 2017-09-08 |
| CN107108684B (zh) | 2020-08-21 |
| EA201791607A1 (ru) | 2018-01-31 |
| US20180002369A1 (en) | 2018-01-04 |
| PE20171322A1 (es) | 2017-09-11 |
| DOP2017000175A (es) | 2017-09-15 |
| PH12017501233A1 (en) | 2017-10-30 |
| CA2973806A1 (fr) | 2016-08-04 |
| JP6722682B2 (ja) | 2020-07-15 |
| CR20170350A (es) | 2017-12-05 |
| JP2018507192A (ja) | 2018-03-15 |
| CO2017007293A2 (es) | 2017-10-31 |
| US10047115B2 (en) | 2018-08-14 |
| ZA201704732B (en) | 2019-02-27 |
| IL252935A0 (en) | 2017-08-31 |
| AU2016212085A1 (en) | 2017-07-20 |
| MX2017009837A (es) | 2018-02-09 |
| EP3250573A1 (fr) | 2017-12-06 |
| AU2016212085B2 (en) | 2018-06-14 |
| BR112017016006A2 (pt) | 2018-03-20 |
| SG11201705077VA (en) | 2017-07-28 |
| CN107108684A (zh) | 2017-08-29 |
| EA031728B1 (ru) | 2019-02-28 |
| CL2017001932A1 (es) | 2018-02-16 |
| WO2016120305A1 (fr) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41415A (fr) | Dinucléotides cycliques utiles pour traiter, entre autres, le cancer | |
| IL283733A (en) | Methods of cancer treatment using activated t cells | |
| IL296080B1 (en) | Method for treating cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| LT4122497T (lt) | Egzonus praleidžiantys oligomerų konjugatai, skirti raumenų distrofijai gydyti | |
| DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
| SI3365373T1 (sl) | Vezne molekule, ki zaviranjo rast raka | |
| IL265335A (en) | Treating cluster headache | |
| IL257252A (en) | Methods of treating fgf21-associated disorders | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| LT4001311T (lt) | Anti-pd-l1/pd-1 deriniai, skirti navikų gydymui | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| IL264451A (en) | Combination treatment for hematological cancers | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| IL260082B (en) | Small molecules against cancer | |
| HRP20190194T1 (hr) | 17a,21-diesteri korteksolona, namijenjeni liječenju tumora | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| IL272027B (en) | Endothal prodrugs for use in treating cancer | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| PT3134119T (pt) | Tratamento do cancro | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| LT3386997T (lt) | Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai | |
| BR112016029236A2 (pt) | métodos para tratar prurido. |